|
|
Blood, 15 December 2006, Vol. 108, No. 13, pp. 4202-4204.
Prepublished online as a Blood First Edition Paper on August 31, 2006; DOI 10.1182/blood-2006-06-026666.
 Previous Article | Next Article 
Submitted June 2, 2006
Accepted July 31, 2006
Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia
Ting-Lei Gu, Valerie L Goss, Cynthia Reeves, Lana Popova, Julie Nardone, Joan MacNeill, Denise K Walters, Yi Wang, John Rush, Michael J Comb, Brian J Druker, and Roberto D Polakiewicz*
Cell Signaling Technology, Inc., Danvers, MA, USA
Oregon Health & Science University Cancer Institute
* Corresponding author; email: rpolakiewicz{at}cellsignal.com.
The 8p11 myeloproliferative syndrome (EMS) is associated with translocations that disrupt the FGFR1 gene. To date, eight fusion partners of FGFR1 have been identified. However, no primary leukemia cell lines were identified that contain any of these fusions. Here, we screened over 40 acute myeloid leukemia cell lines for constitutive phosphorylation of STAT5 and applied an immunoaffinity profiling strategy to identify tyrosine-phosphorylated proteins in the KG-1 cell line. Mass spectrometry analysis of KG-1 cells revealed aberrant tyrosine phosphorylation of FGFR1. Subsequent analysis led to the identification of a fusion of the FGFR1OP2 gene to the FGFR1 gene. siRNA against FGFR1 specifically inhibited the growth and induced apoptosis of KG-1 cells. Thus, the KG-1 cell line provides an in vitro model for the study of FGFR1 fusions associated with leukemia and for the analysis of small molecule inhibitors against FGFR1 fusions.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Hitosugi, S. Kang, M. G. Vander Heiden, T.-W. Chung, S. Elf, K. Lythgoe, S. Dong, S. Lonial, X. Wang, G. Z. Chen, et al.
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth
Sci. Signal.,
November 17, 2009;
2(97):
ra73 - ra73.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. E. Boccalatte, C. Voena, C. Riganti, A. Bosia, L. D'Amico, L. Riera, M. Cheng, B. Ruggeri, O. N. Jensen, V. L. Goss, et al.
The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL
Blood,
March 19, 2009;
113(12):
2776 - 2790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Kruse, M. Bantscheff, G. Drewes, and C. Hopf
Chemical and Pathway Proteomics: Powerful Tools for Oncology Drug Discovery and Personalized Health Care
Mol. Cell. Proteomics,
October 1, 2008;
7(10):
1887 - 1901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Tyner, D. K. Walters, S. G. Willis, M. Luttropp, J. Oost, M. Loriaux, H. Erickson, A. S. Corbin, T. O'Hare, M. C. Heinrich, et al.
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia
Blood,
February 15, 2008;
111(4):
2238 - 2245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chase, F. H. Grand, and N. C. P. Cross
Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome
Blood,
November 15, 2007;
110(10):
3729 - 3734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-l. Gu, T. Mercher, J. W. Tyner, V. L. Goss, D. K. Walters, M. G. Cornejo, C. Reeves, L. Popova, K. Lee, M. C. Heinrich, et al.
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia
Blood,
July 1, 2007;
110(1):
323 - 333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dong, S. Kang, T.-L. Gu, S. Kardar, H. Fu, S. Lonial, H. J. Khoury, F. Khuri, and J. Chen
14-3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells
Blood,
July 1, 2007;
110(1):
360 - 369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
